US$ 20.16
dpp 4 inhibitor and glp 1 agonist Specific actions of GLP-1 receptor agonists DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes Frontiers | Clinical Use of
Description
Further research is warranted to explore long-term outcomes and optimize treatment protocols for this patient population

Effects on adipose tissue GIPRs are abundant in adipose tissue (170)

Albiglutide does not prolong QTc interval in healthy subjects: A thorough ECG study

[DOI] [PubMed] [Google Scholar] 73.Vertongen P, et al
